{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T11:07:37Z","timestamp":1770980857427,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2005,4]]},"DOI":"10.1016\/j.jneuroim.2004.12.001","type":"journal-article","created":{"date-parts":[[2005,2,8]],"date-time":"2005-02-08T10:15:04Z","timestamp":1107857704000},"page":"183-189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Fas polymorphisms are associated with the presence of anti-ganglioside antibodies in Guillain\u2013Barr\u00e9 syndrome"],"prefix":"10.1016","volume":"161","author":[{"given":"Karin","family":"Geleijns","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon D.","family":"Laman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wouter","family":"van Rijs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne P.","family":"Tio-Gillen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rogier Q.","family":"Hintzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter A.","family":"van Doorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart C.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2004.12.001_bib1","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0165-5728(01)00243-0","article-title":"Polyspecific immunoglobulins (IVIg) suppress proliferation of human (auto)antigen-specific T cells without inducing apoptosis","volume":"114","author":"Aktas","year":"2001","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2004.12.001_bib2","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1191\/096120300678828145","article-title":"Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erythematosus","volume":"9","author":"Al-Maini","year":"2000","journal-title":"Lupus"},{"key":"10.1016\/j.jneuroim.2004.12.001_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.it.2003.12.004","article-title":"Guillain\u2013Barr\u00e9 syndrome, a true case of molecular mimicry","volume":"25","author":"Ang","year":"2004","journal-title":"Trends Immunol."},{"key":"10.1016\/j.jneuroim.2004.12.001_bib4","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/ana.410270707","article-title":"Assessment of current diagnostic criteria for Guillain\u2013Barr\u00e9 syndrome","volume":"27","author":"Asbury","year":"1990","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2004.12.001_bib5","first-page":"CR720","article-title":"Serum levels of sTNFR-1 and sFas in patients with relapsing\u2013remitting multiple sclerosis","volume":"8","author":"Bilinska","year":"2002","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.jneuroim.2004.12.001_bib6","first-page":"2397","article-title":"Fas and Fas ligand gene polymorphisms in primary Sj\u00f6gren's syndrome","volume":"27","author":"Bolstad","year":"2000","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jneuroim.2004.12.001_bib7","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1126\/science.7510905","article-title":"Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule","volume":"263","author":"Cheng","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.jneuroim.2004.12.001_bib8","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/ana.410350618","article-title":"Treatment of Guillain\u2013Barr\u00e9 syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study","volume":"35","year":"1994","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2004.12.001_bib9","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jneuroim.2004.01.003","article-title":"Functional polymorphisms in LPS receptors CD14 and TLR4 are not associated with disease susceptibility or Campylobacter jejuni infection in Guillain\u2013Barr\u00e9 patients","volume":"150","author":"Geleijns","year":"2004","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2004.12.001_bib10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1046\/j.1365-2567.2002.01494.x","article-title":"Life and death within germinal centres: a double-edged sword","volume":"107","author":"Guzman-Rojas","year":"2002","journal-title":"Immunology"},{"key":"10.1016\/j.jneuroim.2004.12.001_bib11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/09629359891261","article-title":"Levels of soluble Fas\/APO-1 in patients with Behcet's disease","volume":"7","author":"Hamzaoui","year":"1998","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.jneuroim.2004.12.001_bib12","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0161-5890(97)00081-3","article-title":"Identification and characterization of polymorphisms in the promoter region of the human Apo-1\/Fas (CD95) gene","volume":"34","author":"Huang","year":"1997","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jneuroim.2004.12.001_bib13","first-page":"1183","article-title":"A functional polymorphism in fas (CD95\/APO-1) gene promoter associated with systemic lupus erythematosus","volume":"29","author":"Kanemitsu","year":"2002","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jneuroim.2004.12.001_bib14","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/mus.20076","article-title":"Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system","volume":"30","author":"Kieseier","year":"2004","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2004.12.001_bib15","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1023\/A:1026113222478","article-title":"Fas-beyond death: a regenerative role for Fas in the nervous system","volume":"8","author":"Lambert","year":"2003","journal-title":"Apoptosis"},{"key":"10.1016\/j.jneuroim.2004.12.001_bib16","first-page":"2008","article-title":"Fas promoter \u2212670 polymorphism is associated with development of anti-RNP antibodies in systemic lupus erythematosus","volume":"28","author":"Lee","year":"2001","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jneuroim.2004.12.001_bib17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1044-5323(03)00030-7","article-title":"Function and regulation of the CD95 (APO-1\/Fas) ligand in the immune system","volume":"15","author":"Li-Weber","year":"2003","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.jneuroim.2004.12.001_bib19","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/ard.2003.006056","article-title":"Fas gene promoter polymorphisms in primary Sjogren's syndrome","volume":"63","author":"Mullighan","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jneuroim.2004.12.001_bib20","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s11908-996-0033-5","article-title":"Campylobacter enteritis and the Guillain\u2013Barr\u00e9 Syndrome","volume":"3","author":"Nachamkin","year":"2001","journal-title":"Curr. Infect. Dis. Rep."},{"key":"10.1016\/j.jneuroim.2004.12.001_bib22","first-page":"2575","article-title":"Lymphoproliferative syndrome with autoimmunity: a possible genetic basis for dominant expression of the clinical manifestations","volume":"94","author":"Rieux-Laucat","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2004.12.001_bib23","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0952-7915(03)00042-6","article-title":"Cell-death signaling and human disease","volume":"15","author":"Rieux-Laucat","year":"2003","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jneuroim.2004.12.001_bib24","first-page":"4327","article-title":"Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia","volume":"63","author":"Sibley","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.jneuroim.2004.12.001_bib25","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1182\/blood.V89.4.1341","article-title":"Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis","volume":"89","author":"Sneller","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2004.12.001_bib26","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nm0396-317","article-title":"Fas ligand in human serum","volume":"2","author":"Tanaka","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.jneuroim.2004.12.001_bib27","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","article-title":"A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain\u2013Barr\u00e9 syndrome. Dutch Guillain\u2013Barr\u00e9 Study Group","volume":"326","author":"van der Mech\u00e9","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2004.12.001_bib28","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1212\/WNL.54.3.620","article-title":"Mild forms of Guillain\u2013Barr\u00e9 syndrome in an epidemiologic survey in The Netherlands","volume":"54","author":"van Koningsveld","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2004.12.001_bib29","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1212\/WNL.58.4.610","article-title":"Infections and course of disease in mild forms of Guillain\u2013Barr\u00e9 syndrome","volume":"58","author":"Van Koningsveld","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2004.12.001_bib30","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0140-6736(03)15324-X","article-title":"Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain\u2013Barr\u00e9 syndrome: randomised trial","volume":"363","author":"van Koningsveld","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2004.12.001_bib31","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/(SICI)1098-1136(200006)30:4<373::AID-GLIA60>3.0.CO;2-#","article-title":"Regulation of Fas and FasL expression on rat Schwann cells","volume":"30","author":"Wohlleben","year":"2000","journal-title":"Glia"},{"key":"10.1016\/j.jneuroim.2004.12.001_bib32","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4049\/jimmunol.170.1.132","article-title":"A novel polymorphic CAAT\/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients","volume":"170","author":"Wu","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2004.12.001_bib33","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0165-5728(00)00337-4","article-title":"Dual effect of glucocorticoids on apoptosis of human autoreactive and foreign antigen-specific T cells","volume":"110","author":"Zipp","year":"2000","journal-title":"J. Neuroimmunol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572804004497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572804004497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:00:40Z","timestamp":1759046440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572804004497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":31,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["S0165572804004497"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2004.12.001","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2005,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fas polymorphisms are associated with the presence of anti-ganglioside antibodies in Guillain\u2013Barr\u00e9 syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2004.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}